Clinical Trials Logo

Invasive Pulmonary Aspergillosis clinical trials

View clinical trials related to Invasive Pulmonary Aspergillosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03327727 Terminated - Clinical trials for Invasive Aspergillosis

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

NCT ID: NCT01148160 Terminated - Clinical trials for Invasive Fungal Infection

Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy

Start date: August 2010
Phase: N/A
Study type: Observational

Multiple factors are associated with a large variability in voriconazole exposure following standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug interactions, liver disease, patient age, and genetic polymorphism of the metabolic enzymes. Voriconazole is extensively metabolized by the human hepatic enzymes, primarily mediated by CYP2C19. The polymorphisms account for a relatively large portion of inter-individual variance observed in voriconazole plasma concentrations. However, there are limited data on the relationships between voriconazole blood levels and clinical outcomes or safety in Asian populations. The purpose of this study is to investigate the relationships of voriconazole blood levels with genetic polymorphism, safety, and clinical outcomes in immunocompromised patients with invasive pulmonary aspergillosis.